Q&A with Alexander Fredericks of ToneWell

ToneWell is a next-generation personal wellness company that turns a 30-second voice note into a precise, actionable plan for how to feel and function better — no wearable, no clinic, no lab. We read the signal your voice already carries and translate it into clear next steps you can take that same day.

Here's why now. We've spent a decade handing people more health data than any generation in history — rings, watches, labs, apps — and people feel more confused, not less. They can see everything and still can't answer the only question that matters: what do I actually do today? That gap is the opportunity. ToneWell doesn't add another stream of data; it sits on top of all of it and tells you what to do. The science that reads the voice has matured and is now validated by peer-reviewed institutional research — but the incumbents took it to hospitals and insurers, selling dashboards and risk scores through slow procurement cycles. Nobody took it straight to the consumer with a plan in plain English. That's the white space, and we're already standing in it: the product is live, generating revenue, with 13,000+ scans and an 85% return rate proving demand before we've spent a dollar on acquisition. The timing is the whole thesis — the science is ready, the market is starving for clarity, and the consumer door is wide open.

It proves the two things that kill most early companies are already behind us: people want this, and people come back.

Let me be precise about what these numbers are, because that precision is the point. The 13,000+ scans came from a single product, our flagship Performance Readiness Scan, one general-purpose report. We didn't run thirty experiments to find something that worked. We ran one thing, and it worked. And the 85% return rate is the number I'd ask about if I were you, because return rate is the hardest thing in consumer wellness to manufacture. The category is littered with apps people download, use twice, and abandon. When 85% of people come back to a paid wellness product, they're not being polite — they're getting something they can't get anywhere else. That's product-market fit showing up in behavior, not in a survey.

And here's what makes it trustworthy rather than just impressive: we did it before spending a dollar on paid acquisition. No ad budget inflating the top of the funnel, no growth-hacking the numbers. This is organic demand on a founder-led budget. So when an investor looks at these figures, the question flips from ""will this work?"" to ""how big does it get when it's actually funded?"" That's the entire reason we're raising, not to discover whether the product works, but to pour fuel on a fire that's already lit.

Three things — and they compound.

First, the science. The signal detection that reads the voice isn't something you spin up over a weekend; it's specialized, it's validated by peer-reviewed institutional research, and we hold it under a Master Exclusive License with perpetual rights. A would-be competitor doesn't just need to build a product — they need to go acquire or recreate the underlying science before they can even start. We've already locked that down, permanently.

Second, and this is the part people underestimate, the science was never the hard part. The hard part is the translation. Anyone can show a person a number; almost no one can tell that person what the number means and exactly what to do about it, in plain language, in a way they trust enough to act on and come back for. That translation layer — the workflow, the report architecture, the eight-category prioritization, the way a raw signal becomes ""here's your one move today"", is what we've spent our time and capital building, and it's what the 85% return rate is actually measuring. You can copy a feature. You can't copy the thing that makes people come back.

Third, every scan makes us harder to catch. Each one adds to a proprietary dataset, each new product in our ladder raises the switching cost, and each distribution channel compounds the next. The incumbents in this space pointed their technology at hospitals and insurers and got stuck in procurement. We pointed it at the consumer and built the relationship directly. By the time a larger player decides this category matters, we intend to already own the consumer's trust, their history, and their habit — and that's the one thing capital can't simply buy its way past.